Science News

Early-Onset Parkinson’s in Younger Adults Is Rising Worldwide, Global Study Finds

🧠 What will you learn in this article?

This article highlights a new study published in npj Parkinson’s Disease that set out to assess how common early-onset Parkinson’s disease is around the world and whether that picture has changed over time. Highlights include:

  • Early-onset Parkinson’s disease (EOPD), diagnosed between ages 20 and 49, has become significantly more common worldwide, with cases more than doubling from 1990 to 2021.
  • The sharpest increases were seen among adults in their late 40s and in middle- and upper-middle-income regions, especially East Asia and Andean Latin America.
  • Researchers found associations between higher pesticide use and higher early-onset Parkinson’s rates, though the study does not prove cause and effect.
  • The findings show increased overall EOPD burden, highlighting the need for earlier recognition, more targeted research and support services designed for younger adults living with Parkinson’s.
Woman working from home with family in the background

Parkinson’s disease (PD) is often thought of as a condition that affects older adults — and most of the time, it does. But roughly 5% to 10% of people with Parkinson’s are diagnosed before age 50, a form of the disease known as early-onset Parkinson’s disease (EOPD).

Early-onset Parkinson’s carries a distinct set of challenges. People diagnosed in their 30s and 40s are often at the peak of their careers and raising families, and the disease can affect work, finances, relationships and mental health in ways that differ from a diagnosis later in life. Understanding how many people are affected — and how this varies across the world — is the first step toward directing research and resources to address the problem.

A new study published in npj Parkinson’s Disease set out to assess how common early-onset Parkinson’s is around the world and whether that picture has changed over time. Researchers in China analyzed three decades of data from the Global Burden of Disease Study 2021, a large international project that tracks hundreds of health conditions across 204 countries and territories. They estimated that between 1990 and 2021, the global burden of early-onset Parkinson’s more than doubled.

Study Results

Among adults ages 20 to 49, researchers investigated EOPD burden by looking at:

  1. New cases each year (incidence)
  2. The total number of people living with the disease (prevalence)
  3. Years lived with disability, a standard measure of how much a condition affects daily life

All three roughly doubled or more over the study period. New cases rose from about 28,000 per year in 1990 to about 81,000 in 2021. The total number of people living with early-onset Parkinson’s grew from roughly 190,000 to nearly 484,000.

Some of that increase reflects population growth — there are more people in the world than there were in 1990. But the researchers also calculated age-standardized rates, which adjust for population size and age structure. Those adjusted rates rose too, meaning early-onset Parkinson’s became more common, not just more numerous.

The rising rates were not spread evenly across the age range. Even among adults under 50, risk climbed sharply with each age bracket — people in their late 40s were diagnosed at dozens of times the rate of those in their early 20s. That pattern isn’t surprising, since Parkinson’s risk increases with age. But this oldest bracket also saw the fastest growth over the study period, meaning the rise in early-onset Parkinson’s is being driven largely by people in their late 40s.

The same adjusted rates also reveal that the increase was not evenly distributed worldwide. 

  • In 2021, rates were highest in Andean Latin America — Peru, Bolivia and Ecuador — followed by East Asia, particularly China. 
  • Of the 204 countries and territories studied, more than 170 showed rising rates, with the steepest growth in middle-income and upper-middle-income countries. 
  • Two countries with the fastest-rising rates were China and Norway. 
  • While most regions showed growth in EOPD rates, three regions were exceptions: high-income parts of North America, Central Europe and Central Asia. 

One pattern researchers noticed is that countries with heavier pesticide use per acre of farmland tended to have higher rates of early-onset Parkinson’s. Both Andean Latin America and China have large agricultural sectors with widespread pesticide use. This is a correlation across countries, not proof that pesticides caused these cases, but it lines up with existing research linking pesticide exposure to Parkinson’s risk.

That same idea — chemical exposure — may help explain another pattern in the data. Men had roughly 1.5 times the rates of women, and that gap has widened over time. The researchers suggest that men’s greater occupational exposure to pesticides, industrial chemicals and heavy metals may be one possible explanation, along with the potential protective effects of estrogen in women. 

Highlights

  • The global number of people diagnosed with early-onset Parkinson’s disease — between ages 20 and 49 — more than doubled between 1990 and 2021.
  • New cases rose from about 28,000 per year in 1990 to about 81,000 in 2021
  • People living with EOPD grew from about 190,000 to nearly 484,000.
  • More than 170 of 204 countries showed rising rates. High-income North America was an exception, with rates declining slightly.
  • The steepest growth in early-onset Parkinson’s occurred in middle-income countries, especially in East Asia and Andean Latin America.
  • Higher national pesticide use was associated with higher rates of early-onset Parkinson’s disease.
  • Men were diagnosed with early-onset Parkinson’s at about 1.5 times the rate of women.

What Does This Mean?

This study reminds us that Parkinson’s is not only a disease associated with aging; younger adults are also affected, and the number of younger adults living with it is growing worldwide. Given the earlier age of onset, those diagnosed with EOPD often experience the highest disease burden, spending many years living with PD. 

Accordingly, study authors noted that the increased burden of EOPD may reflect improvements in healthcare and better diagnosis— as health systems improve, more cases of EOPD get identified and recorded, and people live longer with the disease as treatments improve. However, the analysis also demonstrated a clear association between pesticide usage and rates of EOPD, indicating that PD remains closely linked with exposure to environmental contaminants even in younger adults.

Overall, the findings point to a need for earlier recognition of Parkinson’s in younger adults and for research and support services designed with this population in mind.

What Do These Findings Mean for People with Parkinson’s Right Now?

This study provides a global snapshot of the overall burden of early-onset Parkinson’s, not an explanation of what causes PD. However, these findings highlight that Parkinson’s can affect people at younger ages, reinforcing the importance of greater awareness of early- and young-onset PD. In addition, studies like this are needed to help influence policy decisions that ultimately improve the wellbeing of people living with PD. 

Earlier recognition of PD symptoms can help people seek care sooner, potentially leading to living better with PD in the long-term. The study also underscores the unique challenges many people with YOPD face, including managing careers, raising families and navigating financial responsibilities during some of the most active years of their lives.

Learn More

The Parkinson’s Foundation believes in empowering the Parkinson’s community through education. Learn more about early- and young-onset PD through our resources, or by calling our free Helpline at 1-800-4PD-INFO (1-800-473-4636) for answers to your Parkinson’s questions.

Advancing Research

From Golf Courses to Industrial Solvents: Meet the Researcher Investigating Parkinson's Risk

🧠 What will you learn in this article?

This article highlights a researcher studying how much and which kinds of pollutants increase Parkinson’s disease risk. It discusses: 

  • The research of Brittany Krzyzanowski, PhD, recipient of the Clinical Research Training Scholarship in Parkinson’s Disease
  • Which air pollutants are most linked to PD, and where they are most concentrated.
  • How living near a golf course could increase the risk of PD.
  • How this kind of research can guide future public health policies that reduce exposure to pollutants linked to PD.
Brittany Krzyzanowski headshot

Exposure to certain environmental contaminants is increasingly recognized as a risk factor for Parkinson’s disease (PD). Air quality plays a significant role in healthy living, and breathing in polluted air over time can lead to serious medical issues. Growing evidence suggests air pollution could be a risk factor in the development of Parkinson’s disease. However, air pollution comes in many forms from different sources, and it is not understood which types of air pollution are the greatest contributors to PD.

Brittany Krzyzanowski, PhD, is analyzing air quality information from across the U.S. to identify the high-risk pollutants associated with PD and where they are most concentrated. She recently completed this analysis as a recipient of the 2024 Clinical Research Training Scholarship in Parkinson’s Disease funded by the Parkinson’s Foundation and the American Brain Foundation, in collaboration with the American Academy of Neurology.

As a health geographer at the Atria Research Institute in New York City, Dr. Krzyzanowski uses her expertise in geospatial research to analyze environmental data to support prevention of future PD cases. Across the U.S., thousands of air quality monitoring stations, operated by federal, state, and local agencies, record the levels of various pollutants in the air.

“Since receiving the grant, I've been digging deeper into which specific air pollutants are most strongly linked to Parkinson's risk, and the picture is becoming clearer,” said Dr. Krzyzanowski. 

Dr. Krzyzanowski and her team used nationwide Medicare data and tested more than a dozen pollutants, including heavy metals, gases and different components of fine particulate matter (PM2.5) to see which were the strongest predictors of PD risk. 

“Two heavy metals — iron and vanadium — along with ozone showed the strongest associations, with weaker but still notable links to formaldehyde and a component of PM2.5 called sulfate. Because heavy metals and ozone are often tied to traffic and industrial emissions, these results point toward specific, modifiable sources of air pollution that public health efforts could target,” she said.

Dr. Krzyzanowski said her current research into air pollutants builds on two related studies that were recently published with the support of the Parkinson’s Foundation. 

Golf Study Findings

The first study, published in JAMA Network Open, found that older adults living within one mile of a golf course had more than double the odds of developing PD compared with people living more than six miles away, with the strongest associations in areas where drinking water came from vulnerable groundwater sources — suggesting pesticide runoff may play a role.

However, the proximity relationship persisted even after Dr. Krzyzanowski and her team accounted for groundwater vulnerability, and it was stronger in denser, urban areas, which points to airborne pesticide drift as a second, independent exposure route.

TCE Study Findings

In another study, published in Neurology, Dr. Krzyzanowski and team found that people living in areas with the highest levels of the industrial solvent trichloroethylene (TCE) had a higher risk of Parkinson's than those in the lowest-exposure areas. The highest TCE levels were concentrated in parts of the Northeast and Midwest, particularly the Rust Belt.

This information could guide future public health policies that reduce exposure to these pollutants, potentially decreasing the incidence of PD in vulnerable communities.

“Together, these studies reinforce a theme that's central to my research: Parkinson's risk isn't just about how much pollution someone is exposed to, but what kind,” said Dr. Krzyzanowski. “I think about this research as a bridge between data and action. It's not enough to say pollution is linked to Parkinson's risk.”

“Policymakers need to know which pollutants, at what levels, and where, so they can prioritize interventions that actually make a difference,” she said. “Whether that means tightening regulations on industrial solvents like TCE, rethinking pesticide use near residential areas or improving air quality monitoring in high-traffic corridors, my hope is that this work gives communities and decision-makers the specificity they need to act.”

Ready to take action? Visit our Advocacy Center to ask your representatives to support the federal ban on Paraquat, a dangerous chemical linked to PD that is still in use today. 

Policy & Advocacy

Meet the Bill: The Paraquat Prevention Act

🧠 What will you learn in this article?

  • What the Paraquat Prevention Act would do
  • Why reducing paraquat exposure is a Parkinson’s prevention priority
  • Why bipartisan leadership matters
  • How you can raise the issue with Congress
Worker spraying toxic pesticides on plantation

One herbicide that has been linked to Parkinson’s disease (PD) is paraquat, a widely used commercial herbicide in the U.S. On June 18, Representatives Anna Paulina Luna, a Republican representing Florida, and Chellie Pingree, a Democrat representing Maine, introduced the Paraquat Prevention Act.

The bill would ban paraquat across the U.S. People who live or work near where paraquat is sprayed have a higher risk of developing Parkinson’s. If passed, this bill would protect farmers, farmworkers, rural families and other communities from unnecessary exposure.

What would the Paraquat Prevention Act do?

The Paraquat Prevention Act would: 

  • Require the Environmental Protection Agency to cancel the approvals that allow paraquat to be used
  • Implement a zero-tolerance policy for paraquat residue on food
  • Stop the sale and use of paraquat already in stock
  • Prevent paraquat from being approved for future use

Together, these steps would remove paraquat from the U.S. market and protect people regardless of where they live or work.

How can banning Paraquat impact Parkinson’s prevention?

Researchers are still working to better understand what causes Parkinson's, but growing scientific evidence links exposure to paraquat to an increased risk of developing the disease.

One study found that people who sprayed paraquat were more than twice as likely to develop Parkinson's as people who applied other pesticides. Although paraquat has been banned in more than 70 countries, it remains available for agricultural use in the U.S.

Not everyone exposed to paraquat will develop Parkinson's. However, reducing exposure to preventable environmental risks is one way public policy can help create a future where fewer people develop Parkinson's.

“By banning paraquat, the Paraquat Prevention Act would protect Americans and help create a world where fewer people develop Parkinson’s disease in the first place.”

— Andi Lipstein Fristedt, Parkinson’s Foundation Chief Strategy and Policy Officer

Preventing harmful toxic exposures is a public policy priority for the Parkinson’s Foundation. 

Explore more Parkinson's Foundation policy priorities that focus on research, care, prevention and education. 

Building on Progress in the States

States have begun taking action. In May, Vermont became the first state in the country to ban paraquat after advocacy from the Parkinson’s community and other public health groups. Thirteen other states have considered similar proposals this year, with Michigan, New Jersey and Pennsylvania still ongoing.

State action can protect individual communities and build momentum, but a federal ban would provide the same protection to people nationwide.

Support Extends Across Party Lines

Representatives Luna and Pingree come from different political parties and represent different parts of the country. Their partnership reflects the growing recognition that protecting people from harmful environmental exposures should not be a partisan issue.

Voters agree. A national survey found that 67% of registered voters supported banning or limiting paraquat after learning that research has linked it to Parkinson’s. Support increased to 81% after voters learned more about potential exposure risks.

This broad support provides a strong foundation for lawmakers from both parties to come together around the bill.

Help Build Support While Congress Is Home

Introducing a bill is just the first step. It takes public support to build momentum and move legislation forward.

While Congress is in recess this August, members of Congress will return home to meet with constituents at town halls and community events. These meetings are an opportunity to share your Parkinson's story and ask one simple question: Will you support and cosponsor the Paraquat Prevention Act to ban paraquat nationwide? 

Our Advocacy Center has everything you need to find an event, prepare your story and make your voice heard. Not able to attend an event? Join the Parkinson’s Foundation Advocacy Network to receive policy updates and future opportunities to contact Congress.

Raise Awareness

Celebrating Our 2026 National Volunteer Award Recipients

🧠 What will you learn in this article?

This article celebrates 2026 Parkinson’s Foundation National Volunteer Award recipients, recognizing the dedicated volunteers whose leadership, service, fundraising and community-building efforts help advance our mission. It highlights:

  • How each honoree supports and impacts the PD community.
  • Their PD story.
  • How volunteers help us strengthen connections and move research forward.

Volunteers are at the heart of the Parkinson's Foundation mission. Across the country, they raise awareness, build community, support programs, advocate for change and help connect people living with Parkinson's disease (PD) and their families to the resources they need.

Each year, the Parkinson's Foundation recognizes exceptional volunteers through our national volunteer awards. These awards celebrate key people whose service, leadership and dedication have made a lasting impact on the Parkinson's community.

We are proud to introduce our 2026 National Volunteer Award recipients. Meet John, Dale, Jordan, Jen, Rocky and Cindy below — and let their stories inspire you as they have us. 


John with family at a Moving Day event

Paul Oreffice Volunteer of the Year: John Poma 

John embodies the spirit of service. His leadership spans community, state and national levels — from chairing Moving Day Richmond and the Volunteer Leadership Summit to representing Virginia at the Parkinson’s Policy Forum. Through the People with Parkinson's Advisory Council, he has advised on PD GENEration: Powered by the Parkinson’s Foundation, reviewed community grants and encouraged young investigators at the research grantee summit, demonstrating his commitment to advancing science and care.

Beyond his formal roles, John consistently uses his voice to raise awareness of REM sleep behavior disorder and the lived experience of Parkinson's through local and national media. He partners with healthcare providers at Virginia Commonwealth University, a Parkinson’s Foundation Center of Excellence and beyond — including researchers at Mass General and Harvard — to advance the Foundation's mission. John believes in empowering others through education and has spoken at major events, including the Planning for Prevention of Parkinson's conference.

“One of the guiding principles of my longtime professional career in and around healthcare is that helping one person may not change the world, but it may change the world for that one person.”- John Poma

Read John's full story


Dale Picciano waving a flag at a Moving Day event

Rising Star Award: Dale Picciano

Dale’s impact has been extraordinary in a short amount of time. His authenticity, leadership and willingness to openly share his diagnosis have helped break down barriers and create meaningful awareness around PD within the first responder and firefighter communities. By leveraging his lifelong connections, he not only raised significant funds for the Parkinson’s Foundation but also expanded our reach into a passionate and service-oriented network of supporters.

What makes Dale especially deserving of the Rising Star Volunteer Award is the way he channels his own experience into action for others. Rather than stepping back after his diagnosis, he stepped forward — becoming a fighter, advocate, fundraiser and source of inspiration. His dedication perfectly reflects the spirit of courage, community and perseverance that this award represents.

“I am honored and privileged to walk amongst many heroes that are fighters, that won't quit and are fighting back.” – Dale Picciano

Read Dale's full story


Top Fundraiser Award: Jordan Levin, Jen & Rocky Pontikes

Jen and Rocky Pontikes, along with Jordan Levin, transformed one idea into an inspiring movement that united hundreds of people during Parkinson's Awareness Month. Through the Million Meter Challenge, participants rowed, walked, biked and ran together to demonstrate the power of movement while raising critical funds to advance Parkinson's research and improve care.

Jen and Rocky enjoying a glass of wine

What began with Jen's passion for rowing as a way to manage her Parkinson's symptoms grew into a multi-state community effort that inspired more than 300 participants to move more than 24 million meters and raise more than $185,000 for the Parkinson's Foundation. Their creativity, leadership and ability to bring people together exemplify the spirit of this award.

“The Parkinson's Foundation introduced me to an extraordinary community of people living with Parkinson's, care partners, advocates, researchers and healthcare professionals. Through those connections, I found my voice. What began as one of the most difficult moments of my life became my purpose.” - Jen Pontikes                                        

Read Jen and Rocky’s full story

Jordan lifting weights at an event

“My hope is simple: to support the research and education that may one day cure or ease these brutal diseases, and to ensure that caregivers are never left without the information, resources and support they need on their own journey.”- Jordan Levin

Read Jordan's full story


Cindy Finestone

The Nathan Slewett Legacy Community Service Award: Cindy Finestone

Cindy leads by example through extraordinary service to the Parkinson's community. As President of the Parkinson’s Foundation New York Chapter Board, facilitator of the Women with Parkinson's Community Network, Research Advocate and dedicated Moving Day volunteer, she consistently gives her time, leadership and compassion to support others living with Parkinson's.

When Cindy logged her volunteer hours for the year, she wasn't seeking recognition — she simply wanted to ensure the impact of her chapter was reflected. Only then did she realize she had contributed an incredible 339 volunteer hours, a testament to the countless ways she strengthens her local Parkinson's community.

“Being involved in the Parkinson’s Foundation makes me feel like I’m doing something that’s helping. Everything I do is somehow related to the Foundation. I attend a PD support group of 60 women, some of whom have become my closest friends — and I found this group through the Foundation. I call the Helpline for referrals. I go on Parkinson.org every time I feel a new symptom coming."- Cindy Finestone 

Read Cindy's full story


Congratulations to our 2026 award recipients! As we celebrate these six outstanding people, we are grateful for every volunteer who gives their time, talents and passion to help us make life better for people living with Parkinson's.

Explore the many ways you can volunteer with us today. 

My PD Story

John with family at a Moving Day event
People with PD

John Poma

Everyone’s journey with Parkinson’s is unique, and mine began with REM Sleep Behavior Disorder or RBD. In 2018, I experienced episodes of acting out my dreams, which led to a diagnosis of RBD at Virginia Commonwealth University (VCU) Health in late 2019. I was later referred to a movement disorders specialist and enrolled in a RBD research study. Although I did not initially have Parkinson’s disease (PD), my symptoms gradually progressed over time. In 2022, I was diagnosed with Parkinson’s. 

John and his wife at an event

From the earliest days in 2020 of learning about RBD and its connection to Parkinson’s and other synucleinopathy, I made a commitment to become engaged in research and volunteer as a study participant. Learning about the science of Parkinson’s has changed how I see the disease. It gives patients like me a way to move from fear towards hope, purpose and contribution. 

I don’t want to be defined by Parkinson’s and how its symptoms impact me. Instead, I want to be defined by what I have done to make a difference and advance understanding of Parkinson’s. So, instead of feeling defined by Parkinson’s, I began to see how I could contribute to progress. 

It is through my participation in a research program at Massachusetts General Hospital in Boston, MA that I also learned of the important work of the Parkinson’s Foundation. In addition to participating in research, I realized my contribution could also come through patient advocacy, mentorship and education. 

John speaking on stage at a Parkinson's Foundation conference

One of the true privileges of my adult life came in July 2023 when was I was invited to join the Parkinson’s Foundation People with Parkinson’s Advisory Council. 

Living with Parkinson’s and its movement and non-movement symptoms is never easy, and no one day is ever the same. In recent months, living with Parkinson’s has been more difficult for me. However, I have learned that there is something incredibly special about the Parkinson’s community. We are there for each other. We understand what is sometimes difficult for others to understand. And we support each other along the way. 

Friends and family at a Moving Day event

As a member of the advisory council, I learned how our collective voices can change how people understand Parkinson’s; how patients and caregivers are supported; and how research and policy through research programs like PD GENEration (and now also PD GENEration Insights) can accelerate better outcomes. 

I also quickly learned that there is no better way to build community and support the work of the Parkinson’s Foundation than to participate in one of the Parkinson’s Foundation Moving Day events held coast to coast.

Find your nearest Moving Day event now. Ready to do more? Find out how you can get involved!

When you are living with PD, it is not always easy to find the resources that are available to you in the community. Parkinson’s is also a disease that impacts more than just the individual. Instead, it also impacts both your spouse and your family.

When I moved to Richmond in 2022, it was difficult to find the different programs available to people with Parkinson’s in a large urban area. Moving Day changes that and was the reason for my wanting to bring Moving Day to Virginia in 2024. It brings together the many resources available in our community for people with PD and their families. 

John hugging another Moving Day volunteer

We will hold our third Moving Day Richmond, VA, on October 24 at the Richmond Raceway — and I can think of no event that is more meaningful, powerful or uplifting. Moving Day is a celebration of resilience, hope, and the strength of a community determined to change the future of Parkinson’s. 

Moving Day also embraces the power of exercise, which is proven to manage and improve Parkinson’s symptoms. From the earliest days of my diagnosis, I learned that exercise plays a central role in managing Parkinson’s.

The focus of my week is participating as much as my work schedule will allow in a local program called LiftPD. LiftPD is structured around training, therapy and prevention strategies designed to slow progression and maintain function. LiftPD depends heavily on grants and community support, and again, it is my hope that my lived experience with Parkinson’s can help guide and strengthen LiftPD’s efforts to ensure that individuals at every stage of the disease have access to functional exercise programs that enhance mobility, confidence and quality of life.

John with family at a Moving Day event

When I speak, I often say it is an oxymoron to stand here and say I feel lucky. However, I feel incredibly lucky. I am fortunate to have an exceptional care team at VCU Health, and I am grateful for the opportunities I have had to help advance our understanding of Parkinson’s and its future. 

One of the guiding principles of my longtime professional career in and around healthcare is that “Helping one person may not change the world, but it may change the world for that one person.” 

Explore Parkinson’s Foundation volunteer opportunities today.

My PD Story

Jen and Rocky enjoying a glass of wine
People with PD

Jen and Rocky Pontikes

In 2023, I was diagnosed with Parkinson's disease (PD) at the age of 50. To say it was a shock would be an understatement. It was the kind of news that stops you in your tracks and changes everything.

In the beginning, I had a lot of questions and very few answers. My husband, Rocky, and I found ourselves navigating unfamiliar territory while trying to understand what this diagnosis meant for our future and our family. Like so many people living with Parkinson's, I quickly learned that while the diagnosis was life-changing, it did not define us.

While I was still processing my diagnosis, Rocky reached out to the Parkinson's Foundation to learn how he could get involved and support the Parkinson's community. He joined the Parkinson’s Foundation Midwest Chapter early on and became connected to an incredible network of people who understood this journey.

Jen and Rock posing for a picture outside with their sons

For nearly two years, we kept my diagnosis private from our four boys as we worked through it ourselves. Once we finally shared the news, something shifted in me. I decided I was all in. Instead of hiding from Parkinson's, I wanted to learn, connect and help others.

The Parkinson's Foundation introduced me to an extraordinary community of people living with Parkinson's, care partners, advocates, researchers and healthcare professionals. Through those connections, I found my voice. What began as one of the most difficult moments of my life became my purpose.

That purpose inspired Rocky and me to become Parkinson's Champions. We are strong believers in clinical trials, and I have personally participated in two of them. Through these experiences, we developed a deep appreciation for the importance of clinical research and the role it plays in advancing better treatments and outcomes. 

Without these trials, progress stalls. That realization strengthened our commitment to supporting this work in every way we can, including raising awareness and funding for the Parkinson's Foundation.

Jen, Rock, and Jordan

As a planner by nature, I believed that with the right idea and the right team, we could create meaningful impact. We joined forces with fellow Parkinson's Champion and good friend, Jordan Levin, to build a community-wide challenge designed to inspire people to get active while raising awareness and funding for the Parkinson's Foundation.

What began as a competitive rowing challenge quickly evolved into something far more meaningful. We realized the real value wasn't in competition — it was in getting people moving. From there, the challenge expanded beyond rowing to include power walking, running, biking and any form of movement people enjoyed.

In the end, it became less about competition and more about movement, community and coming together in support of a cause that matters deeply to us.

Jen doing yoga

The Million Meter Challenge became something much larger than Parkinson's disease alone. It became a reflection of life itself.

The Million represented connection and community. We didn't have a million people, but it often felt like we did.

The Meters represented movement. Every step, every row, every spin mattered. Nothing was taken for granted.

The Challenge became a reflection of what we can accomplish together through movement, connection and community as the foundation of living well. No one has to endure this disease alone.

Interested in joining the next Million Meter Challenge?

Follow @MillionMeterChallenge on Instagram for updates on future challenges.

Our biggest takeaway was the power of community and the reminder that we are all in this together. We were incredibly proud to watch our Million Meter Challenge movers accomplish things they never thought possible and to see the challenge grow far beyond anything we originally imagined.

Jen and Rock with 3 of their sons

Parkinson's is not a club anyone wants to join. But the Million Meter Challenge showed us that together, anything is possible. It reminded us that health is something we should never take for granted and reinforced one simple but powerful message: Don't wait for disease to knock on your door before you start taking care of your body, your mind and your life.

Through the Parkinson's Foundation, the Million Meter Challenge and the people we've met along the way, I've learned that while Parkinson's changes lives, community changes them too.

Looking back, my diagnosis changed the course of my life in ways I never expected. It also introduced me to a community that helped me find hope, purpose and the confidence to use my voice. 

Jen & Rocky are recipients of the Parkinson’s Foundation Top Fundraisers Award.  Learn how you can become a Parkinson’s Champion today. 

Podcasts

Episode 192: What Your Gut Has to Do with Parkinson’s

Interest in the gut microbiome and its potential role in Parkinson’s disease (PD) continues to grow. Before exploring the latest research, it’s helpful to understand what the microbiome is, the role it plays in overall health, and why researchers are studying its connection to Parkinson’s.

In this episode, we speak with Dr. Lisa Deuel from the University of Vermont Medical Center about what researchers currently know, and don’t know, about the relationship between the gut and Parkinson’s. She explains the gut-brain connection and discusses common gastrointestinal issues experienced by people with Parkinson’s, such as constipation and gastroparesis (limited ability to empty the stomach). She wraps up by sharing practical strategies to support gut health.

Key Takeaways:

  • Research is still limited on whether changes in the gut microbiome may contribute to the risk of developing Parkinson’s disease.
  • Gastrointestinal issues, including constipation and gastroparesis, are common non-movement symptoms of Parkinson’s.
  • Practical Strategies for Supporting Gut Health:
    • Stay hydrated and drink water 
    • Eat a high fiber diet in moderation
    • Consider probiotics 
    • Stay active and moving

Released: July 14, 2026

Raise Awareness

Parkinson’s Genes Explained: 5 Facts about LRRK2

🧠 What will you learn in this article?

This article describes 5 facts about LRRK2, a gene related to Parkinson’s disease: 

  • LRRK2 variants are changes in a Parkinson’s-related gene called LRRK2. These variants can change how brain cells function. 
  • These changes can increase a person’s chance of getting Parkinson’s later in life. 
  • Certain ethnic and ancestral groups have a higher chance of having a LRRK2 variant. 
  • Researchers are closely studying LRRK2 to find new treatments for PD. 
DNA double helix

Genes are the instructions for making the proteins that give us individual characteristics. Just as genes influence traits like eye color or height, sometimes there are changes to a person’s genes — called genetic variants or mutations — that increase the risk of developing certain diseases.

In some people, Parkinson’s disease (PD) can be linked to genetic factors. The PD GENEration: Powered by the Parkinson’s Foundation genetics study found that about 1 in 8 participants has a genetic variant related to Parkinson’s. 

This blog outlines five facts about one of the genes examined in PD GENEration, LRRK2, and why studying it is important for the entire Parkinson’s community. 

The Genetics of LRRK2 

LRRK2 (pronounced “Lark Two”) stands for Leucine-rich repeat kinase 2 and was discovered in 2002. Since then, studies have shown that variations in this gene are related to developing Parkinson’s disease. 

Everyone inherits two copies of the LRRK2 gene — one from each parent. Changes in LRRK2 follow a dominant inheritance pattern, meaning a variant in just one copy of the gene can increase a person’s risk for Parkinson’s disease. 

However, these variants also have “reduced penetrance,” which means that the gene doesn’t act alone to cause Parkinson’s. Whether someone with a LRRK2 variant eventually develops Parkinson’s depends on a combination of genetics and other factors like age and environment. Some people carry a LRRK2 variant but never show symptoms of PD.

1. LRRK2 variants are a common genetic contributor to developing late-onset Parkinson’s. 

PD GENEration, the international research study providing genetic testing and counseling at no cost for people with PD, looks for changes in several Parkinson’s-related genes including LRRK2. To date, PD GENEration has found that:

  • 12% of participants have a variant in one or more of the genes tested.
  • About 2% of participants have a LRRK2 variant.

Most PD (with or without a variant) is considered late-onset, starting later in life and involving changes like slowed movement and shaking.

The way Parkinson’s appears in people with a LRRK2 variant does not look physically different than Parkinson’s in people without this change. Because of the similarities, researchers are investigating whether understanding LRRK2 could open doors to new treatments for all people with Parkinson’s. 

2. Certain ethnic groups are more likely to have LRRK2 variants. 

Different ancestral and ethnic groups can have different risks for genetic diseases. Findings from PD GENEration show that 10.5% of people who identify as Ashkenazi Jewish, 4.0% of people who identify as Berber, and 3.8% of people who identify as Basque carried a LRRK2 variant — compared to 1.2% of people who identified as having none of these ancestries.

People with a higher chance of having a LRRK2 variant can use genetic testing like PD GENEration to better understand their genetic makeup for themselves and their families. 

“For me, it was reassuring to learn that I am a LRRK2 carrier, because then I knew that we had a target. There are clinical studies I can participate in to help advance the field. Within a week of learning that I have a genetic variant, I was participating in research, and I’ve been participating in research ever since.”

-Jessi Keavney, Parkinson’s Foundation Research Advocate

3. A variant in the LRRK2 gene may make it harder for cells to clear out unwanted material. 

The LRRK2 gene gives cells instructions to make the LRRK2 protein, which is responsible for powering the cell and directing nutrients and waste. A variant in LRRK2 can make the protein too active, disrupting the way a cell’s materials are normally transported. 

Research suggests that while LRRK2 normally helps cells clean up and recycle waste, LRRK2 variants may stop this system from working properly. Waste can collect in cells — including in brain cells called neurons. When this happens, the buildup can lead to inflammation and cell death. Early Parkinson’s symptoms appear after the loss of neurons that make dopamine, a chemical that helps the body coordinate movement.

4. LRRK2 is a target for new PD treatments. 

Scientists are highly focused on how mutations in the LRRK2 gene influence Parkinson’s disease. By developing treatments to calm or quiet an overactive LRRK2 gene, researchers hope to protect brain cells and potentially slow or halt the progression of Parkinson’s. 

There are several active clinical trials — studies that test new treatments — for therapies targeting LRRK2 in Parkinson’s. Some studies require a confirmed LRRK2 variant, which can be verified with clinical-grade genetic testing like PD GENEration.   

For those who have already participated in PD GENEration, our PD Trial Navigator program currently partners with Neuron23 for the Neulark trial for LRRK2. For more information about Neulark or other partner trials as they become available, email PDNavigator@parkinson.org. 

5. LRRK2 breakthroughs could benefit the entire PD community. 

Even highly targeted genetic research has the potential to help broader communities. For example, research into a rare genetic condition called familial hypercholesterolemia (FH) helped scientists discover how the body regulates cholesterol. This led to the creation of statins, a medication that lowers cholesterol and is widely used today by people with and without FH.

Enroll in Our Genetics Study

Understanding the connection between Parkinson's and genetics can help us figure out how the disease develops and ultimately the best way it can be treated or cured.

EXPLORE PARKINSON'S-RELATED GENES 
ENROLL NOW

Scientists are hoping LRRK2 research may hold broader promise because of the similarities between LRRK2-related Parkinson’s and the more common idiopathic Parkinson’s — PD without a known cause. What they discover could help many people with Parkinson's in the future. 

Learn More  

The Parkinson’s Foundation works to improve care for people with PD and advance research toward a cure. Learn more with these resources: 

Science News

Two New Studies Show Adaptive Deep Brain Stimulation May Improve Walking in Parkinson’s

🧠 What will you learn in this article?

This article highlights two studies, published in Nature Medicine, that show promise for using new adaptive deep brain stimulation (DBS) methods to treat walking difficulties in Parkinson’s disease (PD). Highlights include:

  • Unlike traditional DBS, adaptive DBS adjusts stimulation in real time based on movement or brain signals. 
  • Both studies identified personalized brain signals (neural biomarkers) to tailor stimulation for specific movement. Both approaches improved walking while preserving traditional DBS benefits for symptoms such as tremors and stiffness.
  • Researchers at Lausanne University Hospital in Switzerland used brain signals to identify and tailor stimulation for different activities. 
  • Researchers the University of California, San Francisco (UCSF) used different brain signals to time and adjust stimulation to participant’s walking rhythm.
Parkinson's Foundation Science News blogs

Deep brain stimulation (DBS) is the most common surgical treatment for Parkinson’s disease (PD). It uses continuous electrical pulses to help control movement symptoms like tremor, stiffness and slowness. For many, DBS can be life changing. Its big shortfall is that it delivers the same stimulation all the time, which does not help with walking difficulties — including unsteady gait, freezing of gait (a sudden inability to move when walking) and falls. These are among the most disabling and dangerous PD symptoms with limited treatment options.

Recently, major advancements have been made in adaptive DBS (aDBS), which is when a DBS device adjusts its stimulation in real time based on a person’s symptoms or behavior. Studies show that aDBS is more helpful for controlling typical “on/off” symptoms (such as tremor and rigidity) compared to traditional DBS treatment. Now, two new studies published in Nature Medicine suggest that aDBS may also hold promise for treating gait impairment in people with Parkinson’s. 

  1. One study, conducted by a team at Lausanne University Hospital in Switzerland, developed a system that uses brain signals to detect which locomotor (the ability to move) activity a person is performing — such as sitting, standing, walking or turning — and selects stimulation settings optimized for that specific activity.
  2. The other study, led by a team at the University of California, San Francisco (UCSF), took a different approach: timing stimulation to specific phases of the walking cycle, footstep by footstep, guided by brain signals unique to each individual participant.

Both studies were small and early-stage but highlight that adaptive DBS could improve walking in ways that traditional DBS cannot. 

Study Results

The primary focus of both studies was whether adaptive DBS settings that target gait are feasible and safe, and whether they could improve walking compared to traditional continuous stimulation. Encouragingly, neither study reported negative events. 

Adaptive DBS was well tolerated in all participants, and both studies found that it still helped manage the movement symptoms — like tremors and stiffness — that traditional DBS provides. Beyond safety, both teams also tracked changes in participants’ walking patterns, including step consistency, symmetry and falls.

2 new adaptive DBS studies graphic

The Swiss study enrolled six people with Parkinson’s who had DBS implants in the subthalamic nucleus. The team used recordings from the implanted DBS device, combined with detailed motion tracking, to develop algorithms that could detect which activity a person was performing — walking on flat ground, avoiding obstacles, turning, etc. — and automatically adjust stimulation settings to match.

  • This approach improved movement across multiple daily activities while preserving the benefits of traditional DBS for other movement symptoms.
  • This system successfully decoded and adjusted to locomotor activities in real time, even as participants’ symptoms changed or took levodopa medication throughout the day — a key challenge for adaptive approaches.

The UCSF study enrolled five people with Parkinson’s who received DBS implants in the globus pallidus region, along with additional recording devices in other brain regions. Using those recordings, they found that the brain produces distinct electrical patterns during specific phases of walking — for example, when the leg swings forward. 

These patterns were unique to each participant, appearing at different frequencies and brain locations. By identifying each person’s individual ‘gait signature,’ the researchers were able to program the neurostimulator to deliver brief boosts of stimulation timed to match each step.

  • During in-clinic testing, this adaptive DBS strategy improved step variability and step symmetry compared to traditional DBS stimulation.
  • Three participants completed a multi-day trial in their own homes, where neither the participants nor the researchers knew which type of stimulation was being used. In this real-world setting, adaptive DBS maintained general movement symptom control and reduced falls.

The UCSF study in this article was supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health. The Parkinson’s Foundation advocates for increased federal funding to advance PD research, improve treatments and move us closer to a cure.

While these are early results need to be confirmed in larger studies, they offer a promising glimpse into a fundamentally new way to address one of the most challenging aspects of Parkinson’s: walking difficulties.

Highlights

  • Two studies, both published in Nature Medicine, tested adaptive DBS systems designed to target movement symptoms that automatically adjust to what a person is doing in real time.
  • Both studies used personalized brain signals, unique to each participant, that specifically indicated different types of movement or activity. 
  • The Swiss study used activity states— for example, recognizing whether a person was sitting, walking, or turning — to switch between optimized stimulation settings.
  • The UCSF study used step-level precision — synchronizing stimulation pulses to the exact rhythm of each individual step – to make adjustments.
  • Both approaches improved walking measures while maintaining the benefits of traditional DBS for other movement symptoms like tremor and stiffness.
  • Neither study reported negative events and showed that these aDBS techniques were well tolerated.
  • Both studies were small (six and five participants). Larger trials are needed to confirm these findings.

What Does This Mean?

Falls are a leading cause of injury and hospitalization for people with Parkinson’s. Since walking is a highly complex activity that requires precise coordination, traditional DBS with consistent stimulation often does not address balance and walking issues. Instead of delivering the same stimulation all the time, adaptive DBS devices adjust in real-time based on the brain’s activity. These studies leveraged this concept to specifically target gait impairment, indicating an important shift in how DBS could help walking symptoms. 

If larger studies confirm these findings, adaptive DBS could offer a meaningful improvement in daily life for people living with Parkinson’s — especially those experiencing gait and balance challenges.

These studies worked by identifying unique, personalized brain signals that were specific to each participant. The algorithms for adaptive DBS were then optimized based on this brain activity — a form of individualized, precision medicine. In addition, the physical location of the participants’ DBS implant varied between studies; the success of both platforms indicates that these treatments can be effective regardless of the DBS implant location, offering hope for more people with Parkinson’s.  

What Does This Mean for People with Parkinson’s?

These studies are in the early stages and have only been tested on a very small number of people. Neither paradigm is ready for widespread clinical use. However, hope lies in the fact that these studies have already moved beyond the lab and are being tested in people living with Parkinson’s. Additionally, the Swiss study used a commercially available DBS neurostimulation device, removing an important barrier to access and suggesting that widespread implementation in the near future may be feasible. 

Next, larger trials will need to confirm the findings to improve features for long-term use and to better understand who would benefit most. People experiencing walking difficulties and falls related to Parkinson’s should talk to their doctor about current treatments and keep an eye out for future adaptive DBS clinical trials. 

Learn More

The Parkinson’s Foundation Helpline (1-800-4PD-INFO) provides answers to questions about PD symptoms and management. Learn more about this topic with the below resources: 

Policy & Advocacy

3 Takeaways from the First National Parkinson’s Project Advisory Council Meeting

🧠 What will you learn in this article?

This article shares key takeaways from the first meeting of the National Parkinson’s Project Advisory Council and explains what it means for the future of Parkinson’s disease (PD) policy. It highlights how:

  • The Council is beginning its work on the first-ever national plan to better diagnose, treat, prevent and cure Parkinson's.
  • The Parkinson's community's years of advocacy made this historic moment possible.
  • There are concrete ways you can stay involved and help shape what comes next.
United States Capitol Building

On June 29, the National Parkinson’s Project Advisory Council held its first meeting, a milestone that was years in the making and a turning point for the Parkinson’s community. 

The Council brings together Parkinson’s experts, government officials, care partners, advocates and people living with Parkinson's disease (PD) to develop the first-ever national plan to better diagnose, treat, prevent and ultimately cure Parkinson's. Michael S. Okun, MD, National Medical Advisor to the Parkinson's Foundation, was appointed to the Council, helping ensure the National Plan to End Parkinson's reflects both scientific expertise and lived experience.

This moment did not happen on its own. It is the result of years of advocacy by people like you. Advocates shared their experiences with Congress to push for the creation of this initiative in 2024. And less than a month after hundreds of advocates went to Capitol Hill this spring urging action on the National Parkinson's Project, the Council was finally seated.

Now the real work begins — and so does our responsibility to keep up the momentum. The Parkinson's Foundation is urging the Council to:

  • Issue its first annual report within one year.
  • Prioritize an estimate of the federal funding needed to address Parkinson's. 
  • Make actionable recommendations to improve care for people living with PD across the lifespan.

What came out of this first meeting? Here are three takeaways:

1. The Council Acknowledged the Urgency to Act

From the outset, leadership from the National Institute of Neurological Disorders and Stroke set a tone of urgency, recognizing that the initiative's initial deadlines had been missed and emphasizing the need for actionable recommendations without further delay. 

Encouragingly, the Council indicated that a report would be delivered in summer 2027, which aligns with our ask that the Council produce its first report within one year. For a disease where there is no time to waste, that commitment to a timeline matters.

2. The Council Acknowledged More PD Resources Are Needed for Care and Research

To meaningfully address Parkinson's, we first need to understand the full costs of the disease — across research and care. The Parkinson's Foundation has been pushing for the Council to develop an estimate of the federal funding needed to prevent, diagnose, treat and ultimately cure Parkinson's, as well as the investment required to improve quality of life for those living with PD today. 

In this first meeting, the Council acknowledged the importance of creating an estimate as they continue their work. This is an important step: a clear picture of what it will take gives Congress the roadmap it needs to determine funding levels and spur meaningful investment.

3. The Parkinson’s Community Showed Up in Force

The energy and public engagement were unmistakable; more than 160 comments were submitted for this first meeting. Ken Chason,  People with Parkinson's Advisory Council Vice Chair and person living with PD, was one of 10 people recognized to present. 

“The Parkinson’s crisis is real and urgent,” Ken wrote in his testimony. “More than 1.1 million Americans have the disease, with approximately 90,000 new diagnoses each year. Parkinson’s is relentlessly progressive, devastating patients and families alike, and is on track to further strain our healthcare system. To fully understand the challenge and chart a way forward, it is essential to hear from people who live with Parkinson’s every day. As the Council begins its work, I urge it to keep the experiences of those living with Parkinson’s in mind.”

Ken drew on his own diagnosis journey to spotlight the community's top priorities: produce the overdue report within one year; identify the resources needed to prevent, diagnose, treat and ultimately cure Parkinson's; and prioritize recommendations to improve access to high-quality care. It was a powerful reminder of what the community can accomplish when it speaks with one voice.

Your Voice Can Shape What Comes Next

The first meeting is only the beginning. The decisions this Council makes over the coming months and years will shape Parkinson's research, care and quality of life for generations. 

The Parkinson's community making its voice heard is critical in making sure the Council  delivers results. You helped create the National Parkinson's Project. Now you can help see it through.

Ready to make a difference? Visit our Advocacy Center to join our Advocacy Network, contact your representatives and take action on the issues that matter most to the PD community today.

Back to Top